Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JS207 + JS212
- Development stage
- Phase 2
- Lead developer
- Junshi Biosciences
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
JS207 + JS212 is an investigational combination of two biologic therapies developed by Junshi Biosciences for the treatment of advanced solid tumors, including metastatic colorectal cancer (mCRC), non-small cell lung cancer (NSCLC), and triple-negative breast cancer (TNBC). JS207 is a recombinant humanized bispecific antibody targeting programmed cell death protein 1 (PD-1) and vascular endothelial growth factor A (VEGF-A), combining immune checkpoint inhibition with anti-angiogenesis. JS212 is a recombinant humanized bispecific antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), conjugated to a topoisomerase I inhibitor payload (exatecan). By combining these two agents, the regimen aims to simultaneously block tumor angiogenesis, enhance antitumor immune responses, and directly target tumor cells expressing EGFR and HER3, potentially overcoming resistance to single-agent therapies.
- Other names
- JS-207 + JS-212JS-212 + JS-207JS207 + JS212JS212 + JS207
02
Targets
EGFR (Epidermal growth factor receptor)PDCD1 (Programmed cell death protein 1 receptor)ERBB3 (Erb-b2 receptor tyrosine kinase 3)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on JS207 + JS212.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JS207 + JS212.